

The synthesis of potential Neramexane metabolites: *cis*- and *trans*-3-amino-1,3,5,5-tetramethylcyclohexanecarboxylic acids

Dina Trifanova,^a Marija Trifonova,^a Aigars Jirgensons,^{a,*} Valerjans Kauss,^a
Osvalds Pugovich,^a Ivars Kalvinsh^a and Guenter Quack^b

^aLatvian Institute of Organic Synthesis, 21 Aizkraukles str., 1006 Riga, Latvia

^bMerz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D-60318 Frankfurt am Main, Germany

Received 22 June 2004; revised 1 September 2004; accepted 7 September 2004

Available online 22 September 2004

Abstract—A seven step synthetic route toward potential Neramexane metabolites *cis*- and *trans*-3-amino-1,3,5,5-tetramethylcyclohexanecarboxylic acids, *cis*-**1** and *trans*-**1**, has been developed from isophorone. The synthetic procedure represents a useful method for the preparation of γ -amino acids with both amino and carboxyl groups situated at tertiary carbon atoms.
© 2004 Elsevier Ltd. All rights reserved.

Neramexane is among NMDA receptor antagonists undergoing phase II clinical trials for the treatment of alcohol abuse.¹ As part of a clinical investigation, we have undertaken studies of Neramexane metabolism in living organisms. Among other metabolic pathways, the complete oxidation of the C3-methyl group of Neramexane by enzymes involved in drug metabolism can be expected, leading to the formation of *cis*- and/or *trans*-3-amino-1,3,5,5-tetramethylcyclohexanecarboxylic acids *cis*-**1** and *trans*-**1** (Fig. 1).² To prove the proposed metabolic pathway using analytical methods like GC/MS or HPLC/MS, it was necessary to prepare potential metabolites *cis*-**1** and *trans*-**1** as reference standards.

γ -Amino acids *cis*-**1** and *trans*-**1** are intriguing synthetic targets since both amino and carboxyl groups are situated at a tertiary carbon atom. Commonly used methods for the synthesis of γ -amino acids with the amino group at a tertiary carbon atom involve conjugate addition of α,α -disubstituted nitro compounds to acrylates and subsequent reduction of the nitro group in the addition product,³ or selective degradation of one carboxyl to an amino group in pentanedicarboxylic acids and masked dicarboxylic acids.⁴ These approaches, however,




Figure 1.


could not be applied to prepare amino acids *cis*-**1** and *trans*-**1** due to difficulties in accessing starting materials.

The Ritter reaction⁵ (reaction of an in situ generated carbenium ion with nitriles) has been used to prepare 3-aminoadamantane-1-carboxylic acid derivatives from 3-hydroxyadamantane-1-carboxylic acid.⁶ Since 3-substituted-1-alkylcyclohexanols are readily available,⁷ this seemed to be an attractive synthetic strategy for the synthesis of aminocyclohexanecarboxylic acids *cis*-**1** and *trans*-**1**. We preferred to use a latent carboxyl group at the desired position in cyclohexane because a carboxyl group is known to retard the Ritter reaction considerably.⁶ Moreover, 1-alkylcyclohexanecarboxylic acids can eliminate CO₂ in strong acidic media.^{5b} A phenyl group⁸ was chosen as an appropriate latent carboxyl group primarily due to its high chemical resistance, and secondly, that it could facilitate the separation of diastereomers at a later stage.


A diastereomeric mixture of 3-phenylcyclohexanols **3** was prepared from isophorone **1** according to the

Keywords: Neramexane; Metabolites; The Ritter reaction; Latent carboxyl group; Oxidation.

*Corresponding author. Tel.: +371 7543503; fax: +371 7553142; e-mail: aigars@osi.lv



Scheme 1. Reagents and conditions: (a) PhMgBr, CuCl, Et₂O, -20 °C, 2 h, 76%; (b) MeLi, Et₂O, 0 °C to rt, 1 h, 82%; (c) TMSCN, H₂SO₄, AcOH, 0 °C to rt, 20 h, separation of isomers (light petroleum ether–ethyl acetate, 10:1, *cis*-4 eluted first followed by *trans*-4), *cis*-4 47%, *trans*-4 29%.



Scheme 2. Reagents and conditions: (a) 20% aq H₂SO₄ reflux 10 h then NaOH until pH ~ 10; (b) Boc₂O, Et₂O, rt, 19 h, *cis*-5 77%, *trans*-5 70% over two steps; (c) RuO₂, NaIO₄, H₂O, CCl₄, CH₃CN, rt, 3 d, 6 40%, 7 68%; (d) 20% aq HCl, reflux, 31 h, then aq NH₄OH, 68%; (e) CF₃CO₂H, CH₂Cl₂, rt, 15 min then aq NH₄OH, 78%.

literature procedure (Scheme 1).⁹ The Ritter reaction of cyclohexanol 3 with hydrogen cyanide¹⁰ (generated in situ from TMSCN) gave a mixture of diastereomeric formamides *cis*-4 and *trans*-4. Gratifyingly, at this point diastereomers *cis*-4 and *trans*-4 were readily separable by flash chromatography on silica gel. An initial attempt to convert the phenyl to a carboxyl group in *N*-formyl aminocyclohexanes 4 using the RuO₂–NaIO₄ oxidizing system^{8a} failed probably due to concomitant oxidation of the formyl group. The formyl group was changed to a *tert*-butoxycarbonyl (Boc) group that was expected to be resistant to the oxidation conditions (Scheme 2). Treatment of *N*-Boc protected 3-phenylcyclohexylamine isomer *cis*-5 with RuO₂–NaIO₄ gave *N*-Boc protected bicyclic lactam 6¹¹ as the major product obviously formed via cyclization of an intermediate *N*-Boc protected aminocyclohexanecarboxaldehyde. Acidic hydrolysis of lactam 6 gave amino acid *cis*-1.¹¹ The *cis*-configuration of amino and carboxyl groups in amino acid *cis*-1 was defined by lactam 6 since no change of configuration at C-1 and C-3 was possible during hydrolysis. The oxidative degradation of the phenyl group in *N*-Boc protected 3-phenylcyclohexylamine isomer *trans*-5 gave, as expected, *N*-Boc protected amino acid 7. The Boc group in compound 7 was removed using standard conditions to yield amino acid isomer *trans*-1.¹¹

In summary, we have developed a seven step synthetic route toward potential Neramexane metabolites *cis*-1 and *trans*-1 from isophorone in 6% and 7% overall yields, respectively. The synthetic procedure represents a useful method for the preparation of γ -amino acids with amino and carboxyl groups situated at tertiary carbon atoms.

Acknowledgements

We acknowledge J. Popelis for obtaining ¹³C NMR spectra and E. Sarule for performing microanalyses. We also wish to thank Dr. R. Zemribo for valuable comments during the preparation of the manuscript.

References and notes

- Danysz, W.; Parsons, C. G.; Jirgensons, A.; Kauss, V.; Tillner, J. *Curr. Pharm. Des.* **2002**, *8*, 434–437.
- Williams, D. A. In *Drug Metabolism. Foye's Principles of Medicinal Chemistry*; Williams, D. A., Lemke, T. L., Eds., 5th ed.; Lippincot Williams & Wilkins: Philadelphia, PA, 2002; pp 174–233.
- (a) Kaji, E.; Igarashi, A.; Zen, S. *Bull. Soc. Chem. Jpn.* **1976**, *49*, 3181–3184; (b) Hill, R. K.; Sawada, S.; Bock, M. G.; Greene, J. R. *Heterocycles* **1987**, *25*, 515–520; (c) Mimura, M.; Hayashida, M.; Nomiyama, K.; Ikegami, S.; Iida, Y. *Chem. Pharm. Bull.* **1993**, *41*, 1971–1986; (d) Newkome, G. R.; Moorefield, C. N.; Epperson, J. D.; Jon, D. *Eur. J. Org. Chem.* **2003**, 3666–3672.
- (a) Wilcox, C. F.; Leung, C., Jr. *J. Org. Chem.* **1968**, *33*, 877–880; (b) Petter, R. C.; Banarjee, S.; England, S. *J. Org. Chem.* **1990**, *55*, 3088–3097.
- (a) Ritter, J. J.; Kalish, J. *J. Am. Chem. Soc.* **1948**, *70*, 4045; (b) Krimen, I.; Cota, D. *J. Org. React.* **1969**, *17*, 213; (c) Bishop, R. In *Comprehensive Organic Synthesis*; Trost, B. M., Ed.; Pergamon: Oxford, 1991; Vol. 6, Chapter 1.9, pp 261–300.
- Shokova, E.; Mousoulou, T.; Luzikov, Y.; Kovalev, V. *Synthesis* **1997**, 1034–1040.
- Jirgensons, A.; Kauss, V.; Kalvinsh, I.; Gold, M. R.; Danysz, W.; Parsons, C. G.; Quack, G. *Eur. J. Med. Chem.* **2000**, *35*, 555–565.
- (a) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. *J. Org. Chem.* **1981**, *46*, 3936–3938; (b) Chakraborti,

- A. K.; Ghatak, U. R. *J. Chem. Soc., Perkin Trans. 1* **1985**, 2605–2610; (c) Banik, B. K. *Synth. Commun.* **1997**, 27, 3637–3656.
9. Shapiro, B. L.; Johnston, M. D., Jr.; Shapiro, M. J. *J. Org. Chem.* **1974**, 39, 796–804.
10. Chen, H. G.; Goel, O. P.; Kesten, S.; Knobelsdorf, J. *Tetrahedron Lett.* **1996**, 37, 8129–8132.
11. *N-tert*-Butoxycarbonyl-1,3,3,5-tetramethyl-6-azabicyclo [3.2.1] octan-7-one **6**: ^1H NMR (200 MHz, CDCl_3): δ 0.89 (3H, s, 3- CH_3); 0.97 (3H, s, 3- CH_3); 1.10 (3H, s, 1- CH_3); 1.24 and 1.26 (total 2H, both d, $J = 14\text{Hz}$, ring protons); 1.40–1.60 (2H, m, ring protons); 1.45 (3H, s, 5- CH_3); 1.52 (9H, s, *t*-Bu); 1.69 (1H, dt, $J = 12\text{Hz}$ and 2Hz, ring proton), and 2.10 ppm (1H, d, $J = 14\text{Hz}$, ring proton); ^{13}C NMR (50 MHz, CDCl_3): δ 21.28, 25.69, 28.05, 30.36, 30.48, 35.87, 43.07, 44.37, 47.37, 49.04, 60.66, 82.38, 150.35, 178.41. *c*-3-Amino-1,3,5,5-tetramethylcyclohexane-*r*-1-carboxylic acid (*cis*-**1**): ^1H NMR (200 MHz, D_2O): δ 0.76 and 0.78 (total 6H, both s, 5,5- CH_3); 0.98 (3H, s, 1- CH_3); 1.21 (3H, s, 3- CH_3); 0.99 (1H, d, $J = 14\text{Hz}$, ring proton); 1.12 (1H, d, $J = 15\text{Hz}$, ring proton); 1.26 (1H, d, $J = 15\text{Hz}$, ring proton); 1.60 (1H, d, $J = 15\text{Hz}$, ring proton); 1.84 (1H, d, $J = 14\text{Hz}$, ring proton), and 2.18 ppm (1H, d, $J = 15\text{Hz}$, ring proton); ^{13}C NMR (50 MHz, CDCl_3): δ 27.15, 32.74, 32.98, 36.44, 45.29, 45.71, 49.90, 50.21, 55.76, 190.16. *t*-3-Amino-1,3,5,5-tetramethylcyclohexane-*r*-1-carboxylic acid (*trans*-**1**): ^1H NMR (200 MHz, D_2O): δ 0.80 (6H, s, 5,5- CH_3); 0.85 (1H, d, $J = 14\text{Hz}$, ring proton); 0.97 (3H, s, 1- CH_3); 1.06 (1H, d, $J = 13\text{Hz}$, ring proton); 1.28 (3H, s, 3- CH_3); 1.13 (1H, d, $J = 13\text{Hz}$, ring proton); 1.51 (1H, d, $J = 13\text{Hz}$, ring proton); 2.00 (1H, d, $J = 14\text{Hz}$, ring proton), and 2.37 ppm (1H, d, $J = 13\text{Hz}$, ring proton); ^{13}C NMR (50 MHz, CDCl_3): δ 27.70, 29.13, 33.34, 34.32, 37.05, 45.72, 48.75, 50.24, 58.18, 187.34.